Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 1 of 1

Pertuzumab approved for routine use in the NHS in England for women with HER2-positive metastatic or recurrent inoperable breast cancer

The drug is recommended, in combination with trastuzumab (Herceptin) and docetaxel, for treating HER2-positive metastatic or locally recurrent unresectable breast cancer